The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells

Zeming Mo, Peixin Du, Guoping Wang, Yongsheng Wang

Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China 610041.

Corresponding author: Yongsheng Wang Telephone Number: 18980602258 Email: wangys75@gmail.com

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2016.12.09; Accepted: 2017.02.27; Published: 2017.06.23

Abstract

A detailed summary of the published clinical trials of chimeric antigen receptor T cells (CAR-T) and TCR-transduced T cells (TCR-T) was constructed to understand the development trend of adoptive T cell therapy (ACT). In contrast to TCR-T, the number of CAR-T clinical trials has increased dramatically in China in the last three years. The ACT seems to be very prosperous. But, the multidimensional interaction of tumor, tumor associated antigen (TAA) and normal tissue exacerbates the uncontrolled outcome of T cells gene therapy. It reminds us the importance that optimizing treatment security to prevent the fatal serious adverse events. How to balance the safety and effectiveness of the ACT? At least six measures can potentially optimize the safety of ACT. At the same time, with the application of gene editing techniques, more endogenous receptors are disrupted while more exogenous receptors are expressed on T cells. As a multi-purpose tool of tumor immunotherapy, gene-engineered T cells (GE-T) have been given different functional weapons. A network which is likely to link radiation therapy, tumor vaccines, CAR-T and TCR-T is being built. Moreover, more and more evidences indicated that the combination of the ACT and other therapies would further enhance the anti-tumor capacity of the GE-T.

Key words: Adoptive T cell therapy; Tumor immunotherapy; Gene-engineered T cell; Tumor associated antigen; Viral vectors and non-viral vectors.

Introduction

The adoptive T cell therapy (ACT) is that T cells are genetically modified to express a chimeric antigen receptor (CAR) or T-cell receptor (TCR) has obtained impressive results in treating multiple types of tumors, such as hematologic malignancies, sarcoma and melanoma, etc. The subjects are conducted a conditioning regimen of lymphodepletion, following the ACT [1-3]. The classical structure of CAR is built with an intracellular costimulatory domain, an intracellular CD3ζ and a chimera of single chain fragment (scFv) of antibodies that can directly target tumor associated antigens (TAA) in a major histocompatibility complex (MHC)-independent manner [4]. Analogously, the α chain and β chain of targeting TAA-specific peptide are concatenated as the activation domain of the TCR-transduced T cells (TCR-T) [5]. The activation of TCR requires the participation of MHC system-dependent peptides-presenting processes. In theory, around 6 × 10⁶−⁷ and up to 12 × 10¹⁰ different peptides can be presented by MHC I and MHC II, respectively [6]. Therefore, based on the diversity of TAA-peptides, TCR α chain and TCR β chain are diverse in fine structure regulation when they identify and bind these peptides in a MHC-dependent manner.

CD19 is expressed on most B malignant cells malignancies, pro-B cells and mature B cells but not on other cell types, which restricts the “on target, off tumor” toxicity when efficient lymphodepletion chemotherapy is given [7]. The CAR-T immunotherapy has induced high remission rates of patients with refractory CD19+ B-cell hematologic malignancies. Excitingly, targeting NY-ESO-1, a cancer germline antigen (CGA) located on the X chromosome [8], has also showed encouraging results in some TCR-T clinical trials. Multiple successful results of CD19-CAR-T and NE-ESO-1-specific TCR-T clinical trials are summarized in Table 1. These results have greatly stimulated the enthusiasm for the exploration of adoptive cell therapy in tumors.
Simultaneously, with the amazing achievements of immune checkpoint inhibitors in clinical trials including lung cancer, melanoma and renal cell carcinoma, the trend of tumor immunotherapy is almost inevitable [9]. Recently, the indispensable value of T cells in anti-tumor effect is further emphasized since FDA approved anti-PD-1 antibody pembrolizumab in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-L1 expression [10]. But, immune checkpoint inhibitors are not perfect. Combination immune checkpoint blockade by ipilimumab and nivolumab, two patients with melanoma developed the fatal myocarditis [11]. A variety of factors will influence the resistance mechanisms to immune-checkpoint blockade, such as genetics, age, HLA type and background chronic infections, et al. [12]. As a multi-purpose tool of tumor immunotherapy, the CAR-T which can produce micro-pharmacies also offers the amazing expectations of anticancer application [13]. Thus, how to confer T cells with more powerful anti-tumor ability? It is becoming a hot research area. Especially, The GE-T plays one of the most important roles. As gene transfer tools, more accurate and safer viral vectors have been used for editing T cell functions, increasingly. Besides, these tools make it possible to finely edit the structure of TAA-special CAR or TCR. In particular, the exploration of GE-T immunotherapy is worth noting in both the United States and China.

The number of CAR-T clinical trials has exploded, particularly in China

Because of the breakthroughs in CAR-T and TCR-T tumor immunotherapy from some preclinical studies, multiple research centers in several countries have conducted hundreds related clinical trials. The development of new antibody of targeting TAA is rare in recent years. So, the types of scFv are relatively scarce, as well. In addition, some cDNAs of scFv have been published. Therefore, the CAR-T manufacturing technology enables rapid replication and propagation. It is easy to find that the number of CAR-T clinical trials is rapidly increasing, especially in China. In 2016, at least twenty-five CAR-T clinical trials have been initiated in China. Comparing in China, the number of newly initiated, published CAR-T clinical trials is maintained in a stable level in the United States. Of course, perhaps the difference in health care policy between China and the United States also was contributed to the divergence of the clinical trials trends. Meanwhile, Israel, Japan, Sweden, United Kingdom, Australia and other countries also have been carried out CAR-T clinical trials in recent years (Figure 1A). When accounted for 40% of the total numbers, CD19-targeted CAR-T is an undoubtedly star product in the history of CAR-T. In addition, as a TAA derived from solid tumors, mesothelin-targeted CAR-T had obtained some encouraging results in pre-clinical studies, especially in regional delivery therapy [14]. At least seven clinical trials of mesothelin-special CAR-T have been or are being carried out at present. Amazingly, a phase I clinical results illustrated that utilizing mesothelin-targeted mRNA-CAR-T cells gene therapy was safe and effective in patients with advanced solid malignancies [15].

The CAR-T targeted antigen spectrum is constantly enriched, including hematologic malignancies TAA, such as CD30, CD20, CD22, ROR1, CD138, BCMA, CD70, LeY [16-23], and also including solid malignancies TAA, such as GPC3, HER2, GD2, EGFR variant III (EGFR vIII), EGFR, CEA, PSMA, Frα, EPCAM, MUC1, ROR1, MUC16<sup>α</sup>, VEGFR2, CD171, PSCA and EphA2, etc (Figure 1B) [24-38].

The clinical trials of TCR-T, the United States outshines others

In contrast to CAR-T, The HLA restriction is one of the most marked characteristics for TCR-T gene therapy. The characteristic increased the difficulty of patients enrolled in the TCR-T clinical trials. For example, because the number of enrollment patients did not meet the expected requirement, a clinical trial was terminated (ClinicalTrials.gov Identifier: NCT00706992). HLA-A*02:01 is a dominant HLA-matched subtype, more than 77% (37/48) of TCR-T clinical trial’s inclusion criteria contained HLA-A*02:01 positive. In addition, some TCR-T clinical trials of targeting NY-ESO-1 and melanoma differentiation antigens MART-1 were terminated, according to low accrual (ClinicalTrials.gov Identifier: NCT00509496, NCT00610311, NCT00612222 and NCT02062359). These terminated trials indicated that it is difficult to find and construct enough effective TCR-T. Peptides derived from the same antigen are very diverse in amino acids and structures. Even from targeting the same TAA, the different peptide/MHC-redirected TCR-T may exhibit different treatment outcomes and adverse effects. For example, two different MART-1-special TCR-Ts, DMF5 TCR-T(against gp100:154-162 epitope) and DMF4 TCR-T(against the gp100:209-217 epitope), which had a significant difference in the outcome of treatment [39, 40]. Therefore, the threshold of TCR-T tumor immunotherapy is higher than CAR-T tumor immunotherapy. The United States has occupied an absolute advantage in the number and the quality of TCR-T clinical trials (Figure 2 A-C).
### Table 1. Some successful clinical trials of CD19-special CAR-T and NE-ESO-1-special TCR-T cancer immunotherapy

| Institution       | TAA transfer tool | Patient populations                                      | Lymphodepleting regimens                      | Infused cells dose | Responses of treatment |
|-------------------|-------------------|----------------------------------------------------------|-----------------------------------------------|-------------------|------------------------|
| **NCI**           | Retrovirus        | child and young adult: ALL; n=21                         | Cy 900 mg/ m² x 1 + Flu 25 mg/ m² x 3d       | 1 × 10⁶ (n=15) vs 3 × 10⁶ (n=4) CAR-T cells/kg | CR: 14/20 (MRD-in 12/14); LFS: 79% at 4.8 mo (MRD- CR patients); OS: 52% at 7.8 mo (all) |
| **FHCR**          | Lentivirus        | adult: NHL; n=52                                        | Cy 2.4 g/m² x 1 + etoposide 100 to 200 mg/m² x 3d | 1 × 10⁸ (n=5) vs 1 × 10⁸ (n=18) CAR-T cells/kg | Cy/Flu:50% CR (9/18), 72% ORR (13/18) VS Cy or Cy/E8% CR (1/12), 50% ORR (6/12) |
| **CHP**           | Lentivirus        | child and young adult: ALL; n=30                         | Cy/VP: Eto100mg/ m² x 2+Cy 440 mg/ m² x 2d | 0.76×10⁶ to 20.6×10⁶ CAR-T cells/kg | CR:90% (27/30); event-free survival rate67% at 6 mo; OS78% at 6 mo |
| **HFCRC**         | Lentivirus        | adult: ALL; n=30                                         | Cy 2.4 g/m² x 1 + etoposide 100 mg/m² x 3d | 1 × 10⁸ (n=13) vs 1 × 10⁷ (n=2) CAR-T cells/kg | 27 of 29 patients (93%) achieved BM remission |
| **NCI**           | Retrovirus        | adult: Mela; n=11                                       | Cy 60 mg/ m² x 2 + Flu 25 mg/ m² x 5 d        | a median of 5.5×10⁹ TCR-T cells/patient(range, 10 to 13×10⁹) | CR: 2/11 in Mela(persisted over 1 year in two patients); ORR:5/11 in Mela; 4/5 in SCS( over 18 months in one patient) |
| **NCI**           | Retrovirus        | adult: Mela; n=20                                       | Cy 60 mg/ m² x 2 + Flu 25 mg/ m² x 5 d        | a median of 5×10⁹ TCR-T cells/patient(range, 0.9 to 13×10⁹) | CR:1/18 in SCS,4/20 in Mela; OR:11/20 in Mela,11/18 in SCS; OS:38% and 14% at 3 and 5 year in SCS, respectively; both 33% at 3 and 5 year in Mela |

CT.GI: ClinicalTrials.gov Identifier; FHCR: Fred Hutchinson Cancer Research Center; CHP: Children's Hospital of Philadelphia; HTUP: Hospital of the University of Pennsylvania; NCI: National Cancer Institute; NHL: non-Hodgkin’s lymphoma; ALL: acute lymphoblastic leukemia; Mela: melanoma; SCS: synovial cell sarcoma; Flu: Fludarabine; Cy: cyclophosphamide; mo: month; Vp: Etoposide; CVAD-B: Methotrexate 1000 mg/m² day1, Cytarabine 1000 mg/m² every 12 hours days 2,3,5; CVAD-A: Cyclophosphamide 300 mg/m² every 12 hours days 1-3, Vincristine 2 mg day 3, Adriamycin 50 mg/m² day 3.

**Figure 1.** CAR-T immunotherapy is rapidly developing in China and CD19 is the dominant TAA (The vast majority of the data comes from: clinicaltrials.gov.)

Figure 1A is indicated the numbers of new initiated CAR-T clinical trials each year and the United States and China account for most of them. But, Israel, Japan, Sweden, United Kingdom and Australia have also carried out similar clinical trials, as well. Figure 1B is indicated the antigen distribution of CAR-T immunotherapy targeting (in total). It is very clearly that CD19 is the dominant TAA. At the same time, a wide variety of TAAs are selected.
As mentioned above, the NY-ESO-1-activated TCR-T clinical trials accounted for more than 30% of all TCR-T clinical trials. Meanwhile, as a TAA, the wilms’ tumor antigen 1 (WT1) is highly expressed in a majority of hematologic malignancies, such as acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), myelodysplastic syndrome (MDS). WT1 was founded in the solid tumors of various tissue origins, such as lung, breast, digestive organs, brain, head and neck, thyroid, and female genital tract, etc [41]. For this reason, it has been developing rapidly that HLA-A*0201-restricted/WT1-specific TCR-T gene therapy for chronic myeloid leukaemia (CML), AML, MDS, NSCLC and mesothelioma. Of course, other tumor associated antigens (TAAs) including MART-1, MAGE-A3, MAGE-A4, gp100, CEA, TIL 1383I, P53, HPV-16 E6, HPV-16 E7 and HBV were also selected as the TCR-T targets (Figure 2 D-F) [42-48].

Although there are a series of the targets of TCR-T and CAR-T, the action of TAA exploration will not stop. On the one hand the heterogeneity of cancer cells may contribute to the difference of antigen distribution, on the other hand the heterogeneous cancer cells still can’t get rid of the majority inherent nature of normal cell. It is very difficult to find antigens or antigenic peptides whose expression level is high enough to activate the signal of specific recognition receptors in cancer tissues while low enough to inactivate the signal of specific recognition receptors in normal tissues. Cancer represents a paradox in which the generality and the heterogeneity coexist. The paradox forms the multidimensional interaction in tumor, TAA and normal tissue.

The multidimensional interaction: tumor, TAA and normal tissue

The complexity and diversity of TAAs make us puzzled, as shown in Figure 1B and Figure 2D. For
example, there are many alternative TAAs to target hematological malignancies. When adoptive CAR-T gene therapy for hematological malignancies, there are lots of TAAs can be selected, such as CD19, CD20, CD30, CD22, CD138, CD70, BMCA, etc. It’s amazing that WT1 and NY-ESO-1 can be selected as targets for TCR-T cancer immunotherapy in hematological malignancies, as well. For solid tumors, it is a more complicated situation. For example, for lung cancer, the candidate TAAs may contain mesothelin, EGFR, MUC1, RORI, CEA, WT1, NY-ESO-1, MAGE-A3/4, etc [49]. A further increase in TAA species is no doubt in the future. Therefore, the concept of tandem CAR has been gradually popular. One encouraging result showed that an adoptive tandem-CAR-T therapy in glioblastomas by targeting heterogeneous expression antigens human epidermal growth factor receptor 2 (HER2) and IL13Ra2 on glioblastomas. The tandem-CAR-T got a better control of cancer through CAR and TCR stimulation in the short term. Moreover, if antigen-activated CAR and antigenic peptide/MHC complex-activated TCR co-exist, what effect will T cells produce? A preclinical study indicated that HER2-special CAR expression in CD8+T cells does not affect stimulation through peptide (SIINFEKL)-activated TCR [51]. Besides, The GE-T cells demonstrated a similar cytotoxic effect through CAR and TCR stimulation in the short term. But, CAR expression was downregulated, and TCR expression was reversely unchanged over the first 20 hours of coincubation. Thus, from 20 to 50 hours, the cytotoxic effect of TCR mediated was better than CAR mediated [51]. Alternatively, the sequential ACT with different targets becomes popular. A clinical trial of the sequential ACT that CD19-targeted CAR-T and CD20-targeted CAR-T for Diffuse Large B Cell Lymphoma (DLBCL) has been executed (ClinicalTrials.gov Identifier: NCT02737085).

It is worth noting that not only diversified TAAs are expressed in one kind of cancer, but also one TAA is expressed in multiple kinds of cancers. For example the NY-ESO-1 is highly expressed in melanoma, multiple myeloma, NSCLC, synovial sarcoma, breast cancer, renal cell cancer, hepatocellular cancer, esophageal cancer, ovarian cancer, bladder cancer, etc [52-54]. Similarly, the mesothelin is highly expressed in mesothelioma and breast cancer, cervical cancer, pancreatic cancer, ovarian cancer, lung cancer and endometrial cancer [55]. Table 2 and Figure 3 provide a good illustration of the multi-dimension interaction. Particularly, when GE-T specifically binds and kills tumors, we cannot ignore that these targeted TAAs may be normally or restrictedly expressed in multiple normal tissues. The multidimensional interactions make the potential toxicity of "on target, off tumor" unavoidable. For instance, the prostate-specific membrane antigen (PSMA) is expressed in prostate cancer, bladder carcinoma, schwannoma, tumor neovasculature of many solid tumors. But it was expressed in not only prostatic acinar cells but also many other normal tissues, including the kidney, small intestine, the central and peripheral nervous system, as well [56].

A wide variety of cytokines are released from the T cells cytotoxic effect and the tumor lysis syndrome, such as TNF-α, IFN-γ, IL-2, IL-6, etc. On the one hand these cytokines enhance anticancer capacity of the GE-T, on the other hand the excessive release of cytokines may induce the T cells exhaustion and the severe cytokine release syndrome (CRS). As serious adverse event, CRS is frequently occurred and potentially caused the fatal complication in the GE-T tumor immunotherapy [57-59]. The GE-T seems as if a double-edged sword. Thus, how we weaken the potential serious adverse effects of GE-T therapy?

### Table 2. The multidimensional interaction of TAAs and tumors in CAR-T gene therapy

| Tumor Associated Antigen | Targeted Tumor | Tumor Associated Antigen | Targeted Tumor |
|--------------------------|----------------|--------------------------|----------------|
| CD19/CD20/CD30/CD22/CD138/CD70/BMCA | Lymphoma, Leukemia | EGFR | Cholangiocarcinoma/Glioma/ Cancer of Lung, Colorectal, Ovary, Pancreatic/Renal, et al |
| MUC1/fecto | Ovarian Cancer / Primary Peritoneal Cancer / Fallopian Tube Cancer | EPICAM | Liver Neoplasms / Stomach Neoplasms |
| Mesothelin | Mesothelioma / Cancer of Breast, Cervical, Pancreatic, Ovarian, Lung, Endometrial, et al | MUC1 | NSCLC/TNBC/Cancer of Hepatocellular, Pancreatic |
| GPC3 | Hepatocellular Carcinoma | RORI | CLL/MLL/ALL/NSCLC/TNBC |
| HER2 | Glioma / Sarcoma / Cancer of Breast, Ovarian, Lung, Gastric, Colorectal, Pancreatic, et al | CEA | Cancer of Lung, Colorectal, Gastric, Breast, Pancreatic, et al |
| GD2 | Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma | EGFRvIII | Glioblastoma |
| | | CD171 | Neuroblastoma |

Footers: CLL: chronic lymphocytic leukemia; MLL: myeloid/lymphoid leukemia; ALL: acute lymphoblastic leukemia; NSCLC: non-small cell lung cancer; TNBC: three negative breast cancer.
The GE-T cancer immunotherapy was followed by fatal serious adverse events

Animal disease models cannot fully reveal the potential risk of fatal serious adverse effect from new drug research and the GE-T is no exception [60]. The antigen co-expression on tumor tissue and normal tissue can easily induce the “on target, off tumor” toxicity [61]. For instance, a carboxy-anhydrase-IX (CAIX)-special CAR-T was administered to 12 patients with CAIX-expressing metastatic renal cell carcinoma (RCC). Unfortunately, these patients who were infused as low as $0.2 \times 10^9$ CAR-T cells would occur the CTC grade 2–4 liver enzyme disturbance and develop necessitated cessation of treatment. The examination of liver biopsies revealed CAIX was expressed on bile duct epithelium in liver [62]. A more common event is B cell aplasia resulting from CD19-redirected CAR-T cells from CD19+ hematological malignancies. The conditioning regimen of lymphodepletion and chemotherapy may contribute B cell aplasia, as well [63, 64]. Even more, some regrettable fatal serious adverse events occurred in the development history of the GE-T tumor immunotherapy. As the events are listed in Table 3, we cannot ignore that the double-edged sword of the GE-T could kill ourselves in some particular conditions, including the clinical trials of CAR-T and TCR-T.

The star drug of Juno Therapeutics, JCAR015, a second generation of CD19-redirected CAR-T, has caused three patients who received the cyclophosphamide + fludarabine (Cy/Flu)-based lymphodepletion to die. The cause of death may be neurologic toxicity, originating from the Cy/Flu regimen to enhance CAR-T cells expansion, persistence and higher response rates. The Cy/Flu regimen also increased the incidence of severe CRS and grade ≥3 neurotoxicity. The speculation was verified in a certain degree in another clinical trial, a phase I/II study of CD19-redirected CAR-T therapy for advanced CD19+ CLL/ALL/Lymphoma with...
defined subsets of CAR-T (NCT01865617). Comparing patients who received Cy-based lymphodepletion without Flu, patients who received Cy/Flu lymphodepletion had higher response rates. Table 1 is a good illustration of the clinical trial results [3]. Maybe the cerebral CRS contributes to the grade ≥3 neurotoxicity. A Chinese clinical trial results demonstrated that cerebral CRS can be triggered by the blood-brain barrier (BBB)-penetrating CD19-directed CAR-T. The cerebral CRS could induce an extremely higher level of IFN-γ and IL-6 in cerebrospinal fluid than in serum [65]. In particular, when we reviewed a clinical trial of the HLA-A*0201/MAGE-A3-positive TCR-T, inducing powerful “on-target off-tumor” toxicity. The cause of death is the cerebral CRS may induce totally different fatal serious adverse event. For example, another clinical trial of HLA-A*01/MAGEA3 (EVPDIGHLY)-special TCR-T gene therapy for melanoma and myeloma was transduced. Two patients who were infused the HLA-A*01/MAGEA3 (EVPDIGHLY)-special TCR-T died within 5 days, due to cardiovascular toxicity. An unrelated peptide derived from the striated muscle-specific protein titin was targeted by the TCR-T, inducing powerful “on-target off-tumor” toxicity [60]. The total infusion doses of GE-T were from 2.4 ×10⁹ to 7.9 ×10¹⁰ cells. Thus, it’s difficult to find an exact death dose. How can we weaken the serious adverse effects of the adoptive GE-T gene therapy?

**Table 3. The clinical trials of adoptive gene-engineered T cell immunotherapy were followed by fatal serious adverse events**

| Institution | Registered of number | TAA | Gene transfer tool | Positive-receptor (scFv or TCR) | Patient populations | Lymphodepleting regimens | Infused cells doses (total) | Time | Cause of death (number of deaths) |
|-------------|----------------------|-----|-------------------|-------------------------------|---------------------|--------------------------|---------------------------|------|----------------------------------|
| **JunoTherapeutics, Inc.** | NCT01753564 | CD19 | Retrovirus | scFv: 19z1-28(2nd) | Relapsed or refractory B-ALL | Cy + Flu | Unknown | Unknown | Neurologic toxicity (3) |
| **Chinese PLA General Hospital** | NCT01352286 | CD20 | Lentivirus | scFv: CAR.201-D137ζ* (2nd) | Diffuse large B-cell lymphoma | COD | 10⁹/kg | 3 weeks | Massive hemorrhage of alimentary tract (1) |
| **National Cancer Institute** | NCT01735604 | HER2 | Retrovirus | scFv: 4D5-CD8-28βζ(3rd) | Colon cancer metastatic to the lungs and liver | Cy 60 mg/kg for 2 days followed by Flu 25 mg/m² for 5 days | 10¹⁰ cells | 5 days | CRS; Speculate that off tumor, targeting lung epithelial Cells (1) |
| **National Cancer Institute** | NCT01735604 | MAGE-A 3/A12 | Retrovirus | TCR: HLA-A*0201-restricted MAGE-A3 peptide: KMAELVHFL | Patient 5: Melanoma 8: esophageal cancer | Cy 60 mg/kg for 2 days followed by Flu 25 mg/m² for 5 days | Patient 5: 7.9 ×10¹⁰ cells | Patient 8: 6.1 ×10⁹ cells |
| **Washington University; the University of Pennsylvania** | NCT01352226 | MAGE-A 3 | Retrovirus | TCR: HLA-A*01-restricted MAGE-A3 peptide: EVPDIGHLY | Patient 1: Melanoma Patient 2: Myeloma | Patient 1: Cy 60 mg/kg for 2 days; Patient 2: Melphalan at 200 mg/m² followed HSCT | 5.3 ×10⁹ cells | 4 days; Patient 2: 5 days | Cardiovascular toxicity (2) |
| **The Netherlands Cancer Institute** | NL.37327.000.11 | MART-1 | Retrovirus | HLA A*0201-restricted MART-1 epitope: EAAIGILTV | melanoma | cy: 60 mg/kg for 2 days followed by Flu 25 mg/m²/day for 5 days | 5×10⁹ cells | 9 days | Multiple organ failure and irreversible neurologic damage (1) |

Time: the span of time from first infused GE-T to death; *: scFv domain targeting the CD20 was derived from AY160760.1; 2nd: the second generation of CAR-T, 3rd: the third generation of CAR-T; CRS: cytokine release syndrome; Cy: Cyclophosphamide; Flu: fludarabine; COD: day 1, Cyclophosphamide, 500 mg/m², day 1, Vincristine, 2 mg, day1-3, Dexamethasone.
The road of optimizing security

Change HLA-restricted type of TCR and insert suicide genes

The disappointing outcomes of the two MAGE-A3-targeted clinical trials did not stop the team of surgery branch, national cancer institute from exploring new MAGE-A3 TCR-T for cancer immunotherapy. An HLA-DPB1*04:01-restricted MAGE-A3 TCR, 6F9 TCR, was isolated from a regulatory T-cell clone which derived from the peripheral blood of melanoma patient after MAGE-A3 vaccination. The MHC class II-restricted TCR-T could specifically target the MAGE-A3 (+) /DP4 (+) cell lines Mel 526-CIITA and H1299-CIITA. Because the HLA-DPB1*04:01 is present in ~ 60% of the Caucasian population, the 6F9-specific TCR-T may have a strong application prospects [67]. In addition, HLA-DP4/NY-ESO-1-specific TCR gene therapy for NY-ESO-1/HLA-DP4-expressing melanoma cells had been constructed at early stage [68, 69]. But it’s difficult to find some significant breakthroughs in the area of HLA-DP4 restriction. Maybe another alternative strategy of optimizing security is the insertion of the suicide genes. Either the herpes simplex virus thymidine kinase (HSV-TK), or inducible caspase 9 safety switch (iCasp9), or a truncated human epidermal growth factor receptor (tEGFR), which confer lethal sensitivity of GE-T according to the anti-herpes drug-ganciclovir, or the small molecule dimerizer, or triggering antibody-dependent cellular cytotoxicity (ADCC) by the infusion of the EGFR-specific monoclonal antibody (mAb) cetuximab, respectively [70-72]. Interestingly, an oligopeptide, Strept-tag II, was introduced into the CD19-directed GE-T. The strep-tag II conferred GE-T many functions, such as marker identification and purification, functional optimization, cell sorting and large-scale cell expansion [73]. All these functions will depend on specific recognition of the antibody to Strept-tag II. In accordance with the principles of ADCC, Strept-tag II is also acted as suicide gene [73].

Reduce affinity of scFv or TCR

The serious adverse effects of multiple clinical trials were due to the high affinity of receptor-antigens. The security may improve when we reduce receptor recognition affinity. For example, a second-generation HER2-specific CAR that scFv was derived from the HER2-specific MAb FRP5 (FRP5-CAR-T), was transduced into T cells. The results of a phase I/II clinical study in recurrent/refractory HER2-positive sarcoma with FRP5-CAR-T demonstrated that the FRP5-CAR-T could persist for 6 weeks without evident toxicities and had a good efficacy of anti-tumor [74]. Similarly, two types of EGFR-special CAR-T were constructed from monoclonal antibodies which differ in affinity. Engineered T cells with low affinity EGFR-CAR not only selectively targeted cells overexpressing EGFR, but also exhibited attenuate effector function as the density of EGFR declined [75].

Non-viral vectors and regional delivery of GE-T

The non-durable target genes expression may be a good choice to improve the security of GE-T. Comparing lentiviral and retroviral vectors technology, the CARs expression using a RNA platform may bypass “on-target, off-tumor” toxic effects according to the property that RNA CAR-T could be completely and rapidly removed as the metabolism of RNA, without depending on suicide genes. For example, C4-27z-directed and C4opt-27z-directed CAR-T, two CAR-Ts targeting folate receptor-α (FRα) expression cancers, exhibited significant proliferation and anti-tumor activity in animal models of human ovarian cancer [76]. Another preclinical data of CD19-directed RNA CAR T cells also illustrated that when multiple reinusions of RNA CAR T cells were administered, the improved survival and sustained antitumor responses were observed in a robust leukemia xenograft model [77]. Another good example comes from CD20-specific RNA CAR-T in dogs with spontaneous B cell lymphoma [78]. These preclinical outcomes undoubtedly enhance the application potential of RNA CAR-T.

The incidence of CRS and “on-target, off-tumor” toxic effects may be enhanced, when GE-T is infused by intravenous, because the incidence that GE-T encounters and binds the normal tissue of co-expression TAAs is increased. It can be very effective in controlling the intensity of CRS that the application of tocilizumab, a monoclonal antibody against interleukin-6 (IL-6), and corticosteroids [79]. But, CRS still cannot be completely eliminated. It may be able to enhance security through the chemical barrier in pleural cavity, abdominal cavity and cranial cavity which limit GE-T excessive systemic diffusion via regional delivery [80]. Therefore, the regional delivery of GE-T is more and more striking. Further, the high concentration of GE-T delivered by local injection may further enhance the therapeutic value of solid tumors. Whether intra-pleurally administered CAR-T targeting mesothelin, regional intraperitoneal (IP) infusion of CAR-T targeting MUC-16ecto and CEA, or intracranial injection of ErbB and IL13Rα-targeted CAR-T, which
were repeatedly proved that regional CAR-T cell infusions for solid tumors of multiple organs may be superior than systemic delivery [14, 34, 81-83].

**Humanized scFv**

What we cannot ignore is that multiple scFvs are derived from murine mAb, such as FMC63 (CD19 targeted), 14G2a (GD2 targeted), Mov19 (FRα targeted), CE7 (CD171 targeted), etc. If we use these scFv to construct CAR-T, there are always risks of graft-versus-host diseases (GVHD) in different species. The innovation for humanized scFv has been going. A humanized CD19-targeted CAR-T showed the same anti-tumor efficacy and prolonged survivability as those were expressed murine scFv [84]. Other humanized scFvs contain chA21 (HER2 targeted), 2173 (EGFRvIII targeted) had been constructed and applied in models of human cancer or clinical studies [84-86].

**Spatiotemporal control of receptor activation**

At the cellular level, other strategies to enhance safety are more vividly described by Christopher A Klebanoff and his colleagues [87]. They make a good summary about the spatiotemporal control of TAA-redirected receptor activation in CAR-T [88-90].

**Stringent examination the potential co-expression of peptides and antigens**

In the clinical treatment level, the inclusion criteria and exclusion criteria of clinical trial need to be strictly implemented. Before the GE-T immunotherapy administration, the co-expression of antigenic peptides or TAAs that are present in normal tissues and organs need to be examined and confirmed, as far as possible. How to recognize and manage the toxicities of CAR-T? Jennifer N. Brudno and James N. Kochenderfer presented some good guidelines for before, during and after tumor immunotherapy of gene-modified T cells [91].

Are all of the above strategies sufficient to drive GE-T into a safe road? It is obviously not enough. When we apply viral vectors of constant insertion, both retroviral vectors and lentiviral vectors, the risk of insertional mutation is the sword of Damocles. Retroviral vectors as gene transfer tool had temporarily cured some inherited disorders by gene-engineered hematopoietic stem cells transplantation, while following the genotoxicity mediated by insertional mutagenesis, including leukemogenesis [92]. Luckily, we still haven't found that genetically modified T cells can be caused leukemogenesis via viral vectors, so far. On the one hand the survival time of genetically modified T cells in clinical subject bodies may be too short to induce tumorigenesis, on the other hand the subjects with tumor may have a greater ability to recognize and kill viral vectors-induced mutant antigens than the ability of patients with inherited disorders. For CAR-T or for TCR-T, maybe the emerge of the sleeping beauty transposon/transposase system (SB) or multiplex artificial nucleases gene editing technology is a reliable strategy for eliminating this potential insertional mutation. But the toxicity of off-target cleavage by artificial nucleases cannot be ignored, as well [93-96].

The road of optimizing security seems to be endless. T cells have been modifying to stronger viability, stronger cytotoxicity capacity, more precise targets identification, and broader applicability. Maybe these modifications are accompanied with new risks. In addition, perhaps tumors are also evolving more intelligent. The GE-T needs to be equipped with enough weapons to fight malignancies (Figure 4).

---

**Figure 4. Some strategies to optimize the security and efficacy of genetically T cells immunotherapy** Six strategies in different directions were applied for optimizing the safety and efficacy of ACT.
The weapons of gene-modified T cells

Although some encouraging clinical trial results were demonstrated from the CAR-T immunotherapy for haematological malignances and TCR-T immunotherapy for melanoma, the GE-T gene therapy is still young, comparing the history of cancers. As mentioned above, the GE-T has to be given some weapons on the road of optimization security and efficacy (Figure 5).

Cytokines and intracellular co-stimulatory signals

Common cytokine-receptor γ-chain (γc) family cytokines, which contains interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21, have critical roles in the development, proliferation, survival and differentiation of T cells [97]. The addition of cytokines during the culture of genetically T cells in vitro has a significant influence on the subsequent immunotherapeutic effect in vivo. Facilitating the formation of memory T cells, IL-7, IL-15 and IL-21 can promote the survival time and long-term anti-tumor effect of CD19-redirected CAR-T and GD2-redirected CAR-T in vivo [98, 99]. A gp100/HLA-A2-directed TCR-T gene therapy was also showed similar results in vitro [100]. One potential risk is IL-7-mediated and IL-15-mediated TCR sensitization enables T cell responses to autoantigens associated with autoimmune disease, such as rheumatoid arthritis (RA) and autoimmune diabetes [101, 102]. Other cytokines, including IL-12 which mediated a second activation mechanism of TCR and led to a 10 to 100 folds increase in persistence and anti-tumor efficacy of ACT in vivo, may be further developed and utilized in the future [103, 104]. At the same time, the CAR that was incorporated IL15 gene also showed a similar therapy effect [105].

Additionally, with the evolution of the costimulatory endodomain in CAR-T that is consisted of the first generation, the second generation and the third generation, it may be confirmed that CD137 (also named 4-1BB) is superior to CD28 for application value. CD137 (also named 4-1BB) was able to attenuate the exhaustion induced by persistent CAR signaling, however, CD28 can accelerate the exhaustion [106]. CD137 confers CAR-T a mild and less terminal differentiation state, which allows CAR-T to survive longer in vivo and may attenuate severe adverse effects while enhancing antitumor effects. It is consistent with the theory that hierarchical T cell exhaustion during chronic infection [58]. The third generation of CAR may confer T cells a higher level of activation and earlier exhaustion tendency. For instance, when we review an attention death event of the HER2-special CAR-T that immunotherapy for metastatic colon cancer, the HER2-special CAR consisted 4D5-CD8-28BBζ, a third generation of CAR-T [25]. Another study was also indicated that CD28-ζ CAR (second generation) was more efficient than the CD28-ζ-OX40 CAR (third generation) [107]. Interestingly, Zhao and colleagues considered a combined CAR that named 1928z-41BBL, including CD19-special scFv, the CD28CD3ζ intracellular domain and 4-1BB ligand (41BBL), could balance effector functions and persistence functions of CAR-T [108]. An interesting thing to note is that these evaluations on the modification of costimulatory signal and the choices for second generation CARs or third-generation CARs were based on viral vectors. Do the same conclusions apply to non-viral vectors? Perhaps the characteristics of the third generation of CAR are more suitable for multiple refinements of GE-T immunotherapy.

The change of target peptide

In contrast to scFv species which is relatively simple, the species of TCR is more diversified. It creates a variety of antigenic peptides and activated TCRs that the complicated repertoire of presented peptides and the subsequent T cell response by MHC system [6]. Petra Simon and colleagues found 16 functional antigen-specific TCRs that specially target the well-known TAA NY-ESO-1 via an integrated approach [109]. However, these TCRs exhibit diverse therapeutic capability, according to the affinity to
recognize MHC-multimers loaded with NY-ESO-1 peptide and the capacity of recognizing endogenously processed antigen [110]. For example, the study of NY-ESO-1/HLA-A*0201-specific peptide 157-165 (SLLMWITQC)-redirected TCR-T immunotherapy for advanced myeloma got an amazing result that clinical responses were observed in 16 of 20 patients (80%), with a median progression-free survival of 19.1 months. In contrast, the anti-tumor ability of NY-ESO-1/HLA-DP4-specific peptide p161-180-redirected TCR-T was much weaker.[61] Another typical case comes from WT1-special TCR-T. Three different TCR-T targeting WT1 peptide, HLA-DRB1*04:05-restricted WT1332, HLA-A*02:01-restricted 9-amino acid peptide (RMFPNAPYL) and HLA-A*24:02-restricted WT1235-243, which were also revealed significant immunotherapy capacity [111-113].

Knockdown of endogenous receptors

The exogenous and endogenous TCR chains which are co-expressed in genetically engineered T cells lead to competition for surface expression and inappropriate pairing, with suboptimal vitality and potentially harmful unpredicted specificities. The knockdown of endogenous TCRs will confer a higher level of expression and more efficient antigen recognition of exogenous TCRs. Even more, the knockout of endogenous TCRs will reduced the probability of TCR gene transfer-induced graft-versus-host-disease [113]. The knockdown can be achieved by nucleases genome editing, contained zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALEN), CRISPR/Cas9 and megaTAL nucleases, or by RNA interfere (RNAi). The megaTAL nucleases and CRISPR/Cas9 seem to have better disruption efficiency and low levels of toxicity and off target cleavage [96, 114]. In order to confer more capacity on genetically modified T cells, increasingly, more and more endogenous receptors have been knocked down. A "Off-the-Shelf" CD19-targeted CAR-T that was deficient in expression of both their αβ T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent, was allogeneic transplanted to CD19+ tumor patient. Even in the presence of the chemotherapeutic agent, the "Off-the-Shelf" CAR-T was still able to effectively destroy CD19+ tumors. It is an idealized third-party CAR T immunotherapy product [115]. Similarly, a triple genome editing that simultaneously disrupts the genes of TCR, beta-2 microglobulin (B2M) and programmed cell death gene-1(PD-1) in CAR-T by using CRISPR/Cas9 system. The deficient of CAR-T provide an alternative as a universal donor to adoptive T cells therapy for cancers [116]. The small hairpin RNA (shRNA) could also blockade cell-intrinsic PD-1 in CAR-T [117]. Another alternative is that viral vectors encode anti-immunosuppressive factors antibodies while expressing a specific receptor. For example, a human CAIX-targeted CAR-T was engineered to secrete human anti-programmed death ligand 1 (PD-L1) antibodies [118]. As more and more GE-T is demanded for diversification functions, more and more endogenous receptors will be abolished.

The most valuable thing is that the knockdown of endogenous receptors is equally applicable to both CAR-T and TCR-T, in most cases.

Flexible use of tumor vaccines

The early injection of tumor vaccines is an effective and relatively safe way to isolate antigenic peptide-positive TCRs. It is widely used in TCR-T cancer immunotherapy [2, 61, 119]. For a long time, independent of MHC system has been considered the unique advantage of CAR-T immunotherapy. However, with the difficult progress in the solid tumor treatments, we need to find a reliable path to break through solid tumor additional obstacles that contain immunosuppressive microenvironment, membrane antigen mutagenesis, tumor cell heterogeneity, et al. A fully humanized CAR which selectively and especially targeted the HLA-A*02:01/alpha-fetoprotein (AFP) 158-166, ET1402L1-CAR, was transduced into T cells via a pCDH lentiviral vector. ET1402L1-special CAR-T was shown robust anti-tumor activity in vivo by intravenous administration or intraperitoneal injection [120]. This result is interesting, because it can be served as a bridge between cancer vaccines, CAR-T and TCR-T.

Optimized T cell subsets

T cells are divided into many subsets, such as CD4+ T cells, CD8+ T cells, central memory TCM, effector memory TEM cells, or regulatory T cells. In tumor immunotherapy, the single subset of GE-T may not be the best choice. A clinical trial which CD19 CAR-T cells were manufactured from defined T cell subsets in a 1:1 CD4+/CD8+ ratio to 32 adults with relapsed and/or refractory B cell non-Hodgkin’s lymphoma was verified the important of optimized T cell subsets [3]. At the same time, along with the technology of T cells amplification and sorting in vitro to further improve, more functional ratio of T cell subset will be further exploited.

Combination therapy for cancer

In the course of cancer treatment, the ACT can be existed alone, or acted as a part of the combination therapy. For example, a human IgG1 T-cell receptor
mimic monoclonal antibody directed to a peptide (RMFPNAPYL) of WT1 in HLA-A*02 dependent was therapeutically effective, alone and in combination with tyrosine kinase inhibitors (TKIs), against a leukemia with the most common, pan-TKI, gatekeeper resistance mutation, T315I [111]. Whether WT1-targeted TCR and the mimic monoclonal antibody combination therapy will produce a similar effect? If so, this strategy will become an option for TKIs resistance in cancer therapy. As noted above, tumor vaccines have a unique advantage in inducing TAA-specific TCR. The tumor radiotherapy can produce a similar effect. The vaccine-similar effect was contributed non-redundant immune mechanisms in cancer by a combination of radiotherapy and dual checkpoint blockade [121]. Maybe it is a very imaginative treatment combination that ACT is combined with radiation therapy.

**Engineering neoantigen-reactive T cells**

Perhaps in the future, it can be implemented that relying on high-throughput sequencing technology to find tumor specific antigens (TSA) which are caused by mutations. Neoantigen is one of the TSA. Using the technology of high-throughput TCR gene-capture to search neoantigen-reactive TCR and constructing neoantigen-targeted TCR-T are no longer distant [87, 122]. Here, the high-throughput sequencing technologies not only become a link between TSA and activated receptors, but also act as a booster for customizing GE-T. It is possible to develop more precise ACT, depending on the TAA expression assay of individual tumor cells. But, the sad fact gene therapy is the expensive treatment. The overwhelming majority of patients cannot afford the cost of gene therapy, including GE-T tumor immunotherapy [123].

In summary, the functions of T cell are continuously developed. More and more weapons will be added to the menu of personalized treatment. However, with the abundance weapons being applied, tumors may undergo modulation and deletion of TAA. Tumors may resistant to chemotherapy, radiotherapy, targeted therapy, and immunotherapy in combination therapy. The arms race is far from over.

**Abbreviations**

PD-1: programmed death-1 receptor; NSCLC: non-small cell lung cancer; HLA: histocompatibility leukocyte antigen; ROR1: tyrosine kinase-like orphan receptor 1; BCMA: B-cell maturation antigen; LeY: Lewis (Le)-Y; GPC3: Glypican-3; HER2: human epidermal growth factor receptor-2; GD2: The tumor-associated ganglioside GD2; EGFR: epidermal growth factor receptor; CEA: carcinoembryonic antigen; PSMA: prostate-specific membrane antigen; FRα: folate receptor-alpha; EPCAM: epithelial cell adhesion molecule; MUC1: mucin 1; VEGFR2: vascular Endothelial Growth Factor Receptor-2; PSCA: prostate stem cell antigen; EphA2: erythropoietin-producing hepatocellular carcinoma A2; HPV: human papillomavirus; MAGE: melanoma-associated antigen-encoding gene; TNF-α: tumor necrosis factor-α.

**Authorship**

Conception and design: Zeming Mo, Peixin Du, Guoping Wang, Yongsheng Wang

Administrative support: Yongsheng Wang;
Collection and assembly of data: Zeming Mo

Data analysis and interpretation: Zeming Mo;

Manuscript writing: All authors

Final approval of manuscript: All authors

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507-17.
2. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21: 1019-27.
3. Cameron J TL, Carolina B, Michael H, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016; 8: 358ra116.
4. Semmerneyer D, Hudecek M, Kosain PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016; 30: 492-500.
5. Cyrille J CZ, Regina B, Yangbing Z, et al. Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bispecific Retroviral Vector Encoding a Murine Anti-p53 TCR. Journal of immunology. 2005; 175: 5799-808.
6. Rock KL, Reits E, Neeftjes J. Present Yourself! By MHC Class I and MHC Class II Molecules. Trends in immunology. 2016;37:724-37.
7. Ghoshishan S, Pule M, Amrolia P. CD19 chimeric antigen receptor T cell therapy for haematological malignancies. British journal of haematology. 2015; 169: 465-78.
8. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009; 100: 2014-21.
9. Wolchock JD. PD-1 Blockers. Journal of Cancer. 2017, Vol. 8.
10. [Internet] FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer. 2016. http://www.mercknewsroom.com.
11. Johnson DB, Balco JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine. 2016; 375: 1749-55.
12. Pitt JM, Yezziou M, Daillere R, et al. Resistance Mechanisms to Immune-Checkpoint Blockade. New England Journal of Medicine. 2016; 375: 1749-55.
13. Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell. 2016; 167: 405-18 e13.
14. Adusumilli PS, Cherkassky I, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014; 6: 26ra151.
15. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2: 112-20.
16. Wang C WZ, Wang Y, Guo Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin’s lymphoma: an
42. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and
41. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. 
40. Marybeth SY, Mark ED, Zheng ZL, et al. Transfer of a TCR Gene Derived from
39. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second
generation CAR T cell against the LEY antigen in acute myeloid leukemia. Mol Ther. 2013; 21: 2229.
38. Huang J, Liang J, Tang Q, et al. An active murine-human chimeric Fab
37. Künkele A, Taraseviciute A, Finn LS, et al. Preclinical Assessment of
36. Huang J, Liang J, Tang Q, et al. An active murine-human chimeric Fab
35. Hillerdal VRM, Leja J, Essand M. Systemic treatment with CAR-engineered T 
34. Kandalaft LE, Powell DJ, Jr, et al. A phase I clinical trial of adoptive transfer of
33. Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for
32. P S. Haematological cancer: Anti-BCMA CAR T cells show promise in MM. Jpn J Clin Oncol. 2016; 12: 863-71.
31. Kandalaft LE, Powell DJ, Jr, et al. A phase I clinical trial of adoptive transfer of
30. Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for
29. Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for
28. Kong TT, Wang Y, Wang W, et al. Novel T-cell receptor recognizing ERBB2. Mol Ther. 2010; 18: 43-51.
27. Morgan RA, Yang JC, Kitanu M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18: 843-51.
26. Louis CU, DBlich, Pule M, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011; 118: 6030-6.
25. Morgan RA, Yang JC, Kitanu M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18: 843-51.
24. Li W, Guo L, Rathi P, et al. Redirecting T Cells to Glypican-3 with 4-1BB Zeta
23. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second
generation CAR T cell against the LEY antigen in acute myeloid leukemia. Mol Ther. 2013; 21: 2229.
22. Li W, Guo L, Rathi P, et al. Redirecting T Cells to Glypican-3 with 4-1BB Zeta
21. P S. Haematological cancer: Anti-BCMA CAR T cells show promise in MM. Jpn J Clin Oncol. 2016; 12: 863-71.
20. Brian G. TM, Wang J, Qian XJ, et al. CD20-specific adoptive immunotherapy cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2009; 114: 535-46.
19. Huang J, Liang J, Tang Q, et al. An active murine-human chimeric Fab
18. Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for
17. Brian G. TM, Wang J, Qian XJ, et al. CD20-specific adoptive immunotherapy cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2009; 114: 535-46.
16. Zhang Z, Linette GP, Maus MV, et al. Cardiovascular toxicity and titin
15. Li W, Guo L, Rathi P, et al. Redirecting T Cells to Glypican-3 with 4-1BB Zeta
14. Huang J, Liang J, Tang Q, et al. An active murine-human chimeric Fab
13.казенное учреждение НИИ ФА WOMEN’S HEALTH -18. 755-63.
12. Zhou J, Liu H, Hu X, et al. Long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS one. 2013; 8: e61338.
11. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016; 9: 70.
10. Asquith PA, Staudt MA, Binder-Scholl GK, et al. NK-T1-specific TCR-engineered T cells mediate potent and selective killing of antigen-specific antitumor effects in mice. Nature medicine. 2015; 21: 914-21.
9. Lammers CH, Steijlen P, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and molecular profiling of on-target and off-target effects. J Immunother. 2013; 36: 133-51.
8. Brenjes RJ, Riviere I, Park BH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118: 8177-28.
7. Davila ML, Koss CC, Gurnet G, et al. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS one. 2013; 8: e61338.
6. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016; 9: 70.
5. Morgan RA, Chirnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36: 133-51.
4. Yao X, Ly, Parker LL, Li YF, et al. Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T Cell-Receptor for Cancer Immunotherapy. J Immunother. 2016; 39: 191-201.
3. Mandic M, Castelli F, Janic K, et al. One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DRA and HLA-DPA Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma. The Journal of Immunology. 2005; 174: 6055-62.
2. Davila ML, Koss CC, Gurnet G, et al. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS one. 2013; 8: e61338.
1. Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016; 9: 70.
http://www.jcancer.org
101. Deshpande P, Cavanagh MM, Le Saux S, et al. IL-7- and IL-15-mediated TCR
transduced primary T cells. Cancer Immunol Immunother. 2010; 59: 2891-2911.
102. Chen XL, Bobbala D, Rodriguez GM, et al. Induction of autoimmune diabetes in
non-obese diabetic mice requires interleukin-21-dependent activation of
autoimmune CD8(+) T cells. Clin Exp Immunol. 2013; 173: 184-94.
103. Braun M RM, Yoo YE, Scholz CJ, et al. IL-12-mediated sensitizing of T-cell
receptor-dependent and -independent tumor cell killing. Oncology immunology.
2016; 5: e1188245.
104. Rubinstein MP, Su EW, Suriano S, et al. Interleukin-12 enhances the function
and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol
Immunother. 2015; 64: 539-49.
105. Hoyos V, Savolado B, Quintarelle C, et al. Engineering CD19-specific T
lymphocytes with interleukin-15 and a suicide gene to enhance their
anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24: 1160-70.
106. Long AH, Hao WM, Shern JF, et al. 4-IBB costimulation ameliorates T cells
exhaustion induced by tonic signaling of chimeric antigen receptors. Nature
medicine. 2015; 21: 381-90.
107. Hombach AA, Rapp G, Ahsen H. Arming cytotoxic-driven killer cells with
chimeric antigen receptors: CD28 outperforms combined CD28-4-1BB
"super-stimulation". Mol Ther. 2013; 21: 2266-77.
108. Zhao Z, Condones M, van der Stegen SJ, et al. Structural Design of Engineered
Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Cancer cell. 2015; 28: 415-28.
109. Simon P, Omokoko TA, Breitkreuz A, et al. Functional TCR retrieval from
single-antigen-specific human T cells reveals multiple novel epitopes. Cancer
Immunol Res. 2014; 2: 1283-94.
110. Semmerneder D, Hornig H, Kröning H, et al. NY-ESO-1 antigen-reactive T cell
receptors exhibit diverse therapeutic capability. Int J Cancer. 2013; 132: 1360-7.
111. Dubrovsly V, Pankov D, Brea EJ, et al. A TCR-mimic antibody to WT1
bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.
Leukemia. 2016; 30: 1239-48.
112. Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cell immunotherapy
using a WT1-specific TCR vector encoding silencers for endogenous TCRs
shows marked antileukemia reactivity and safety. Blood. 2011; 118: 1495-503.
113. Katsuhara A, Aoyama F, Tanii N, et al. Transduction of a novel
H LA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells
confers killing activity against human leukemia cells. Anticancer research.
2015; 35: 1251-6.
114. Bunse M, Bendle GM, Linnemann C, et al. RNA-mediased TCR knockdown
prevents autoimmunity in mice caused by mixed TCR dimers following TCR
gene transfer. Mol Ther. 2014; 22: 1983-91.
115. Pourot L, Philip B, Schiffer-Manniosi C, et al. Multiplex Genome-Edited T-cell
receptors (MGeTRs) enhance anti-CD19 CAR T-cell activities in xenograft
models. Cancer Res. 2015; 75: 5353-64.
116. Ren JX, Fang C, Jiang S, et al. Multiplex genome editing to generate general
CAR T cells resistant to PD1 inhibition. Clinical cancer research. 2016; 6: 970-8.
117. Cherkassky L, Morrello A, Villena-Vargas J, et al. Human CAR T cells with
cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Journal of Clinical Investigation. 2016; 126: 3130-44.
118. Suarez ER GD, Sun J, Sui J, et al. Chimeric antigen receptor T cells secreting
anti-PD-L1 antibodies more effectively repress renal cell carcinoma in a
humanized mouse model. Oncotarget. 2016; 7: 34341-55.
119. Chapuis AG, Ragnonsson GB, Nguyen HN, et al. Transferred WT1-reactive
CD8+ T cells mediate antileukemic activity and persist in post-transplant
patients. Sci Transl Med. 2013; 5: 174ra27.
120. Liu H, Xiang YJ, Long L, et al. Targeting alpha-fetoprotein (AFP)-MHC
complex with CAR T cell therapy for liver cancer. Clinical cancer research.
2016; 22: 1723-36.
121. Twymann-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual
checkpoint blockade activate non-redundant immune mechanisms in cancer.
Nature. 2015; 520: 373-7.
122. Linemann C, HV, Vithlberg P, Kline RJ, et al. High-throughput identification
of antigen-specific TCRs by TCR gene capture. Nature medicine. 2013; 19: 1534-41.
123. Orkin SH, Reilly P. Paying for future success in gene therapy. Science. 2016;
352: 1059-61.